September 2025: JWCA advises Alnylam on its new $500 million inaugural revolving credit facility in conjunction with its upsized $661 million convertible and capped call offering
September 2025: JWCA advises Alnylam Pharmaceuticals on its upsized $661 million convertible and capped call transaction to retire a portion of its outstanding convertible notes
September 2022: JWCA advises Alnylam Pharmaceuticals on its inaugural $1,035 million convertible and capped call transaction